166 related articles for article (PubMed ID: 17000683)
1. Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs.
Kloft C; Wallin J; Henningsson A; Chatelut E; Karlsson MO
Clin Cancer Res; 2006 Sep; 12(18):5481-90. PubMed ID: 17000683
[TBL] [Abstract][Full Text] [Related]
2. Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression.
Hansson EK; Wallin JE; Lindman H; Sandström M; Karlsson MO; Friberg LE
Cancer Chemother Pharmacol; 2010 Apr; 65(5):839-48. PubMed ID: 19680655
[TBL] [Abstract][Full Text] [Related]
3. Mechanism-based models for topotecan-induced neutropenia.
Léger F; Loos WJ; Bugat R; Mathijssen RH; Goffinet M; Verweij J; Sparreboom A; Chatelut E
Clin Pharmacol Ther; 2004 Dec; 76(6):567-78. PubMed ID: 15592328
[TBL] [Abstract][Full Text] [Related]
4. The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia.
Hansson EK; Friberg LE
Cancer Chemother Pharmacol; 2012 Apr; 69(4):881-90. PubMed ID: 22057837
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors.
Mould DR; Holford NH; Schellens JH; Beijnen JH; Hutson PR; Rosing H; ten Bokkel Huinink WW; Rowinsky EK; Schiller JH; Russo M; Ross G
Clin Pharmacol Ther; 2002 May; 71(5):334-48. PubMed ID: 12011819
[TBL] [Abstract][Full Text] [Related]
6. A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy.
Latz JE; Karlsson MO; Rusthoven JJ; Ghosh A; Johnson RD
Cancer Chemother Pharmacol; 2006 Apr; 57(4):412-26. PubMed ID: 16322990
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic model of topotecan-induced time course of neutropenia.
Zamboni WC; D'Argenio DZ; Stewart CF; MacVittie T; Delauter BJ; Farese AM; Potter DM; Kubat NM; Tubergen D; Egorin MJ
Clin Cancer Res; 2001 Aug; 7(8):2301-8. PubMed ID: 11489805
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
[TBL] [Abstract][Full Text] [Related]
9. Model-based neutrophil-guided dose adaptation in chemotherapy: evaluation of predicted outcome with different types and amounts of information.
Wallin JE; Friberg LE; Karlsson MO
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):234-42. PubMed ID: 20050841
[TBL] [Abstract][Full Text] [Related]
10. Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy.
de Graan AJ; Loos WJ; Friberg LE; Baker SD; van der Bol JM; van Doorn L; Wiemer EA; van der Holt B; Verweij J; Mathijssen RH
Clin Cancer Res; 2012 Aug; 18(16):4425-32. PubMed ID: 22645049
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring of 21-day oral etoposide in patients with advanced non-small cell lung cancer.
Miller AA; Tolley EA; Niell HB
Clin Cancer Res; 1998 Jul; 4(7):1705-10. PubMed ID: 9676845
[TBL] [Abstract][Full Text] [Related]
12. Indirect-response model for the time course of leukopenia with anticancer drugs.
Minami H; Sasaki Y; Saijo N; Ohtsu T; Fujii H; Igarashi T; Itoh K
Clin Pharmacol Ther; 1998 Nov; 64(5):511-21. PubMed ID: 9834043
[TBL] [Abstract][Full Text] [Related]
13. Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients.
Bulitta JB; Zhao P; Arnold RD; Kessler DR; Daifuku R; Pratt J; Luciano G; Hanauske AR; Gelderblom H; Awada A; Jusko WJ
Cancer Chemother Pharmacol; 2009 May; 63(6):1035-48. PubMed ID: 18791717
[TBL] [Abstract][Full Text] [Related]
14. Once-daily gentamicin dosing in children with febrile neutropenia resulting from antineoplastic therapy.
Inparajah M; Wong C; Sibbald C; Boodhan S; Atenafu EG; Naqvi A; Dupuis LL
Pharmacotherapy; 2010 Jan; 30(1):43-51. PubMed ID: 20030472
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacodynamic factors in docetaxel toxicity.
Puisset F; Alexandre J; Treluyer JM; Raoul V; Roché H; Goldwasser F; Chatelut E
Br J Cancer; 2007 Aug; 97(3):290-6. PubMed ID: 17595656
[TBL] [Abstract][Full Text] [Related]
16. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
[TBL] [Abstract][Full Text] [Related]
17. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.
Friberg LE; Henningsson A; Maas H; Nguyen L; Karlsson MO
J Clin Oncol; 2002 Dec; 20(24):4713-21. PubMed ID: 12488418
[TBL] [Abstract][Full Text] [Related]
18. Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy.
Latz JE; Rusthoven JJ; Karlsson MO; Ghosh A; Johnson RD
Cancer Chemother Pharmacol; 2006 Apr; 57(4):427-35. PubMed ID: 16322992
[TBL] [Abstract][Full Text] [Related]
19. Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach.
Sun W; O'Dwyer PJ; Finn RS; Ruiz-Garcia A; Shapiro GI; Schwartz GK; DeMichele A; Wang D
J Clin Pharmacol; 2017 Sep; 57(9):1159-1173. PubMed ID: 28419480
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel.
Fetterly GJ; Grasela TH; Sherman JW; Dul JL; Grahn A; Lecomte D; Fiedler-Kelly J; Damjanov N; Fishman M; Kane MP; Rubin EH; Tan AR
Clin Cancer Res; 2008 Sep; 14(18):5856-63. PubMed ID: 18794097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
